Open AccessFibroblast Growth Factor-23 and the Long-Term Risk of Hospital-Associated AKI among Community-Dwelling Older Individuals
Author(s) -
Jeremiah R. Brown,
Ronit Katz,
Joachim H. Ix,
Ian H. de Boer,
David S. Siscovick,
Morgan E. Grams,
Michael G. Shlipak,
Mark J. Sarnak
Publication year - 2013
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.05830513
Subject(s) - medicine , hazard ratio , interquartile range , cystatin c , quartile , creatinine , renal function , fibroblast growth factor 23 , proportional hazards model , fgf21 , albuminuria , kidney disease , confidence interval , biomarker , risk factor , fibroblast growth factor , parathyroid hormone , biochemistry , chemistry , receptor , calcium
AKI occurs frequently in older persons. Elevated circulating fibroblast growth factor-23 (FGF-23), a known marker of impaired mineral metabolism, may also reflect tubular dysfunction and risk of AKI. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom